Quinupristin dalfopristin adverse reactions

# Adverse Reactions
The safety of Synercid was evaluated in 1099 patients enrolled in 5 comparative clinical trials. Additionally, 4 non-comparative clinical trials (3 prospective and 1 retrospective in design) were conducted in which 1199 patients received Synercid for infections due to Gram-positive pathogens for which no other treatment option was available. In non-comparative trials, the patients were severely ill, often with multiple co-morbidities or physiological impairments, and may have been intolerant to or failed other antibacterial therapies.

## Comparative Trials
Adverse Reaction Summary  All Comparative Studies
Safety data are available from five comparative clinical studies (n= 1099 Synercid; n= 1095 comparator). One of the deaths in the comparative studies was assessed as possibly related to Synercid. The most frequent reasons for discontinuation due to drug-related adverse reactions were as follows:
Additional adverse reactions that were possibly or probably related to Synercid with an incidence less than 1% within each body system are listed below:

### Body as a Whole
Abdominal pain, worsening of underlying illness, allergic reaction, chest pain, fever, infection;

### Cardiovascular
Palpitation, Phlebitis;

### Digestive
Constipation, dyspepsia, Oral Moniliasis, Pancreatitis, Pseudomembranous Enterocolitis, Stomatitis;

### Metabolic
Gout, peripheral edema;

### Musculoskeletal
Arthralgia, Myalgia, Myasthenia;

### Nervous
Anxiety, Confusion, Dizziness, Hypertonia, Insomnia, Leg Cramps, Paresthesia, Vasodilation;

### Respiratory
Dyspnea, Pleural Effusion;

### Skin and Appendages
Maculopapular Rash, Sweating, Urticaria;

### Urogenital
Hematuria, Vaginitis

## Clinical Reactions  Skin And Skin Structure Studies
In two of the five comparative clinical trials Synercid (n=450) and comparator regimens (e.g., oxacillin/vancomycin or cefazolin/vancomycin; n=443) were studied for safety and efficacy in the treatment of complicated skin and skin structure infections. The adverse event profile seen in the Synercid patients in these two studies differed significantly from that seen in the other comparative studies. What follows is safety data from these two studies.
Discontinuation of therapy was most frequently due to the following drug related events:

## Non-Comparative Trials

### Clinical Adverse Reactions
Approximately one-third of patients discontinued therapy in these trials due to adverse events. However, the discontinuation rate due to adverse reactions assessed by the investigator as possibly or probably related to Synercid therapy was approximately 5.0%.
There were three prospectively designed non-comparative clinical trials in patients (n = 972) treated with Synercid. One of these studies (301), had more complete documentation than the other two (398A and 398B). The most common events probably or possibly related to therapy were:

## Laboratory Events
The most frequently observed abnormalities in laboratory studies were in total and conjugated bilirubin, with increases greater than 5 times upper limit of normal, irrespective of relationship to Synercid, reported in 25.0% and 34.6% of patients, respectively. The percentage of patients who discontinued treatment due to increased total and conjugated bilirubin was 2.7% and 2.3%, respectively. Of note, 46.5% and 59.0% of patients had high baseline total and conjugated bilirubin levels before study entry.

## Other
Serious adverse reactions in clinical trials, including non-comparative studies, considered possibly or probably related to Synercid administration with an incidence <0.1% include: acidosis, anaphylactoid reaction, apnea, arrhythmia, bone pain, cerebral hemorrhage, cerebrovascular accident, coagulation disorder, convulsion, dysautonomia, encephalopathy, grand mal convulsion, hemolysis, ]. Cases of hypotension and gastrointestinal hemorrhage were reported in less than 0.2% of patients.

## Post-Marketing Experiences
In addition to adverse events reported from clinical trials, reports of angioedema and anaphylactic shock have been identified during post approval use of Synercid.